Last reviewed · How we verify
Minocycline HCl Microspheres
Minocycline HCl microspheres deliver the antibiotic minocycline directly into periodontal pockets to inhibit bacterial growth and reduce inflammation in periodontal disease.
Minocycline HCl microspheres deliver the antibiotic minocycline directly into periodontal pockets to inhibit bacterial growth and reduce inflammation in periodontal disease. Used for Chronic periodontitis (adjunctive to scaling and root planing).
At a glance
| Generic name | Minocycline HCl Microspheres |
|---|---|
| Also known as | Arestin (brand name), minocycline, Arestin |
| Sponsor | OraPharma |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosome |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Periodontics |
| Phase | FDA-approved |
Mechanism of action
Minocycline is a tetracycline-class antibiotic that penetrates bacterial cell membranes and inhibits protein synthesis by binding to the 30S ribosomal subunit. The microsphere formulation provides sustained, localized release of minocycline within the periodontal pocket, achieving high local concentrations while minimizing systemic exposure. This targeted delivery reduces pathogenic bacteria and inflammatory mediators associated with periodontitis.
Approved indications
- Chronic periodontitis (adjunctive to scaling and root planing)
Common side effects
- Tooth discoloration
- Gum irritation
- Oral candidiasis
- Allergic reaction
Key clinical trials
- Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics (EARLY_PHASE1)
- Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities (NA)
- Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg (PHASE4)
- Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients (PHASE4)
- Systemic Markers of Inflammation: 9- and 12-Month Follow-Up Post Non-Surgical Periodontal Therapy
- Lycopene vs Minocycline Hydrochloride as Adjunctive to Periodontal Treatment (PHASE2)
- Kidney and Periodontal Disease Study (NA)
- Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline HCl Microspheres CI brief — competitive landscape report
- Minocycline HCl Microspheres updates RSS · CI watch RSS
- OraPharma portfolio CI